Callan Family Office LLC Takes Position in Smith & Nephew SNATS, Inc. $SNN

Key Points

• Callan Family Office LLC has acquired a new stake in Smith & Nephew SNATS, Inc., purchasing 8,165 shares valued at approximately $250,000 in the 2nd quarter.
• Several institutional investors have also increased their holdings, with Bessemer Group Inc. boosting theirs by 3,471.4% during the first quarter.
• Smith & Nephew's stock is currently trading at $35.79, showing a 1.2% increase and a market capitalization of $15.28 billion.

Callan Family Office LLC purchased a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 8,165 shares of the medical equipment provider's stock, valued at approximately $250,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in shares of Smith & Nephew SNATS by 22.4% during the first quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock worth $103,000 after buying an additional 666 shares during the last quarter. QRG Capital Management Inc. grew its stake in shares of Smith & Nephew SNATS by 2.5% in the 1st quarter. QRG Capital Management Inc. now owns 85,534 shares of the medical equipment provider's stock valued at $2,427,000 after purchasing an additional 2,095 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Smith & Nephew SNATS by 37.7% in the first quarter. Oppenheimer Asset Management Inc. now owns 53,590 shares of the medical equipment provider's stock valued at $1,520,000 after purchasing an additional 14,677 shares during the period. Moran Wealth Management LLC raised its stake in shares of Smith & Nephew SNATS by 1.4% during the first quarter. Moran Wealth Management LLC now owns 117,385 shares of the medical equipment provider's stock worth $3,330,000 after purchasing an additional 1,570 shares during the last quarter. Finally, Bessemer Group Inc. lifted its holdings in shares of Smith & Nephew SNATS by 3,471.4% during the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after purchasing an additional 1,701 shares during the period. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Stock Up 1.2%

Smith & Nephew SNATS stock opened at $35.79 on Friday. Smith & Nephew SNATS, Inc. has a fifty-two week low of $23.69 and a fifty-two week high of $38.79. The firm has a market capitalization of $15.28 billion, a price-to-earnings ratio of 16.57, a price-to-earnings-growth ratio of 0.96 and a beta of 0.69. The stock's fifty day moving average is $36.70 and its two-hundred day moving average is $31.65. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00.

Smith & Nephew SNATS Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 3rd will be paid a $0.285 dividend. This represents a yield of 165.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS's payout ratio is presently 26.39%.

Wall Street Analysts Forecast Growth

SNN has been the topic of several recent research reports. Canaccord Genuity Group boosted their price objective on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a "hold" rating in a research note on Monday, August 18th. Sanford C. Bernstein set a $37.50 target price on shares of Smith & Nephew SNATS and gave the company a "market perform" rating in a report on Tuesday. Weiss Ratings reiterated a "hold (c+)" rating on shares of Smith & Nephew SNATS in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a research report on Friday, October 3rd. Eight analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Smith & Nephew SNATS presently has a consensus rating of "Hold" and an average target price of $36.75.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.